Department of Advanced Medicine in Biotechnology and Robotics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Cell Transplant. 2010;19(6):887-92. doi: 10.3727/096368910X509013. Epub 2010 Jun 29.
Cell therapy is a proven and efficient method for treating multiple diseases. For both basic research and clinical practice, the development of noninvasive in vivo imaging methods is essential for monitoring the trafficking or homing of transplanted cells. One attractive approach for the effective imaging of transplanted cells is the efficient labeling of cells with a contrast agent. In this study, we developed a novel contrast agent of magnetic resonance imaging (MRI), TMADM-02. TMADM-02 was efficiently transduced into cells without toxicity. However, the aggregation of TMADM-02 was observed because of its low stability in culture medium. Therefore, TMADM-02 may have led to a false-positive test result. In future studies, we should verify not only the efficiency of labeling cells but also the stability of the contrast agent of MRI for clinical applications.
细胞治疗是一种经过验证且有效的治疗多种疾病的方法。对于基础研究和临床实践，开发非侵入性的体内成像方法对于监测移植细胞的迁移或归巢至关重要。一种用于有效成像移植细胞的有吸引力的方法是使用造影剂对细胞进行高效标记。在这项研究中，我们开发了一种新型磁共振成像（MRI）造影剂 TMADM-02。TMADM-02 能够在没有毒性的情况下高效转染细胞。然而，由于其在培养基中的低稳定性，观察到 TMADM-02 的聚集。因此，TMADM-02 可能导致了假阳性的测试结果。在未来的研究中，我们不仅应该验证细胞标记的效率，还应该验证 MRI 造影剂的稳定性，以用于临床应用。
